Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSB462 (luxdegalutamide) plus abiraterone in metastatic hormone-sensitive prostate cancer
NL-OMON59867Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2025
- Modality
- Small Molecules, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of luxdegalutamide and abiraterone in prostate cancer (PCa) (3 arms), sponsored by Novartis. Primary endpoints: PSA90 rate, Safety and 1 more. Started Oct 2025; status: active, not recruiting.
02
Drugs
luxdegalutamideabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON59867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59867.